Qingqing Pang

机构：Liuzhou Maternal and Child Health Hospital, Liuzhou General Hospital, Fourth Affiliated Hospital of Guangxi Medical University

发表论文 20 篇 · 总被引 69 次 · h-index 4

代表论文

• Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages (2025 · Hepatology · 被引 27)
• Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004) (2025 · JHEP Reports · 被引 7)
• Survival benefit of hepatectomy after complete or partial response to conversion therapy in unresectable hepatocellular carcinoma (GUIDANCE003): a multi-center study (2025 · Liver Cancer · 被引 6)
• Postoperative hepatitis B virus reactivation and its impact on survival in HBV-related hepatocellular carcinoma patients undergoing conversion therapy with interventional therapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors (2025 · Frontiers in Cellular and Infection Microbiology · 被引 5)
• Prognostic value of LODDS in late-onset gastric adenocarcinoma: analysis of SEER, TCGA, and external multicenter cohorts (2025 · Frontiers in Oncology · 被引 4)
• Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages (2025 · Hepatology · 被引 4)